NAOV 0.55 NanoVibronix, Inc.
Range: | 0.459-1.64 | Vol Avg: | 37990 | Last Div: | 0 | Changes: | -0.05 |
Beta: | 1.51 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu May 28 2015 | Empoloyees: | 10 |
CUSIP: | 63008J108 | CIK: | 0001326706 | ISIN: | US63008J6038 | Country: | US |
CEO: | Mr. Brian M. Murphy | Website: | https://www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.